A recent inquest into the death of a 34-year-old man has raised concerns over the safety of medical cannabis prescriptions issued through private clinics, particularly when provided without adequate review or coordination with existing psychiatric care. Oliver, who died by suicide in November 2023, had been prescribed high-strength medical cannabis following a single video consultation in 2022, despite a history of recurrent depression, prior psychiatric hospital admissions, and a diagnosed cannabis dependency. His treating psychiatrists had warned that cannabis use hindered his recovery.

The coroner’s ruling in January concluded that the cannabis prescription played a significant role in Oliver’s death. It highlighted the absence of communication between the private clinic and Oliver’s psychiatric team, noting that the cannabis prescriptions impeded his access to necessary psychiatric and addiction services. The coroner further cautioned that without reform, similar fatalities might occur.

This development comes as Boots, a major UK pharmacy chain, recently launched a medical cannabis service offering prescriptions after video consultations. Boots has pledged to implement “strong clinical safeguards” to ensure patient safety. However, critics question the effectiveness of such measures, pointing out that the company’s website lists cannabis addiction as a “common myth,” contradicting clinical evidence of cannabis dependency, including in Oliver’s case. Present regulations do not mandate the safeguards that might prevent such outcomes.

Advocates for reform, including Oliver’s family, emphasize the need for stricter prescribing protocols. Their campaign, known as Oliver’s Law, proposes compulsory face-to-face assessments prior to prescribing cannabis, mandatory screening for addiction risks and other contraindications, and obligatory consultation with any treating psychiatrists. They argue that many conditions for which cannabis is prescribed—such as chronic pain and neurological disorders—often coincide with depression and substance use disorders, where caution is advised.

Private medical cannabis prescriptions in the UK have more than doubled between 2023 and 2025, reaching 1.8 million in 2025. A recent investigation revealed that just ten doctors accounted for half of all UK cannabis prescriptions. Professor Henrietta Hughes, the Patient Safety Commissioner, warned that the rapid growth in cannabis prescribing has outpaced the development of adequate patient safety systems.

Efforts by Oliver’s family to engage multiple government departments and regulatory bodies have been met largely with responses outlining the limits of their respective responsibilities. Advocates express concern that government priorities may favor the financial interests of cannabis clinics over patient protection.

Boots maintains that its priority is responsible, clinically led care and has stated support for robust safeguards. Campaigners urge the company to endorse regulations that would apply to all medical cannabis providers. Oliver’s family emphasizes that he, described as gentle and kind, deserved better protection, and so do all patients seeking medical cannabis treatment in the future.